Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fishbane

Showing results (231-240 of 357) with videos related to

Pageof 36
Sort By:
Kidney International|May 7, 1999
Bone histology in patients with nephrotic syndrome and normal renal functionS K Mittal, S C Dash, S C Tiwari, et al.
Kidney International|June 26, 2009
Posttransplant anemia: the role of sirolimusSteven Fishbane, David J Cohen, Daniel W Coyne, et al.
Kidney International|September 13, 2003
Hemoglobin variability in epoetin-treated hemodialysis patientsJeffrey S Berns, Hafez Elzein, Robert I Lynn, et al.
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|November 12, 2013
Longitudinal predictors of uremic pruritusShayan Shirazian, Myriam Kline, Vipul Sakhiya, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|December 20, 2021
Dose effect analysis of sodium zirconium cyclosilicate in hemodialysis patientsBruce Spinowitz, Kieran McCafferty, Steven Fishbane, et al.
Kidney Medicine|August 30, 2022
Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial ProgramSteven Fishbane, Warren Wen, Catherine Munera, et al.
Clinical Nephrology|August 10, 2012
Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patientsSteven Fishbane, W Kline Bolton, Wolfgang C Winkelmayer, et al.
Clinical Therapeutics|July 10, 2007
Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal diseaseAnatole Besarab, Moro O Salifu, N Martin Lunde, et al.
Journal of the American Society of Nephrology : JASN|January 14, 2017
Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency AnemiaSteven Fishbane, Geoffrey A Block, Lisa Loram, et al.
Clinical Kidney Journal|October 18, 2024
Chronic kidney disease-associated pruritus and quality of life with difelikefalin treatment: a <i>post hoc</i> analysis of phase 3 data using the Skindex-10 questionnaireSonja Ständer, Steven Fishbane, Thilo Schaufler, et al.
Pageof 36

Showing results (231-240 of 357) with videos related to

Sort By:
Pageof 36
Kidney International|May 7, 1999
Bone histology in patients with nephrotic syndrome and normal renal functionS K Mittal, S C Dash, S C Tiwari, et al.
Kidney International|June 26, 2009
Posttransplant anemia: the role of sirolimusSteven Fishbane, David J Cohen, Daniel W Coyne, et al.
Kidney International|September 13, 2003
Hemoglobin variability in epoetin-treated hemodialysis patientsJeffrey S Berns, Hafez Elzein, Robert I Lynn, et al.
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|November 12, 2013
Longitudinal predictors of uremic pruritusShayan Shirazian, Myriam Kline, Vipul Sakhiya, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|December 20, 2021
Dose effect analysis of sodium zirconium cyclosilicate in hemodialysis patientsBruce Spinowitz, Kieran McCafferty, Steven Fishbane, et al.
Kidney Medicine|August 30, 2022
Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial ProgramSteven Fishbane, Warren Wen, Catherine Munera, et al.
Clinical Nephrology|August 10, 2012
Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patientsSteven Fishbane, W Kline Bolton, Wolfgang C Winkelmayer, et al.
Clinical Therapeutics|July 10, 2007
Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal diseaseAnatole Besarab, Moro O Salifu, N Martin Lunde, et al.
Journal of the American Society of Nephrology : JASN|January 14, 2017
Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency AnemiaSteven Fishbane, Geoffrey A Block, Lisa Loram, et al.
Clinical Kidney Journal|October 18, 2024
Chronic kidney disease-associated pruritus and quality of life with difelikefalin treatment: a <i>post hoc</i> analysis of phase 3 data using the Skindex-10 questionnaireSonja Ständer, Steven Fishbane, Thilo Schaufler, et al.
Pageof 36